SCHEMBL14677366

SCHEMBL14677366

O=C(O)Cc1ccc2oc(-c3cccnc3)cc2c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.65
CYP26A1 O43174 1/20 0.61
CYP26B1 Q9NR63 1/20 0.61
FFAR1 O14842 6/20 0.56
S1PR1 P21453 1/20 0.56
PIM1 P11309 1/20 0.55
PIM2 Q9P1W9 1/20 0.55
ALDH1A1 P00352 2/20 0.49
NPC1 O15118 1/20 0.49
MAPK1 P28482 1/20 0.49
NAPRT Q6XQN6 1/20 0.49
TP53 P04637 2/20 0.48
MEN1 O00255 1/20 0.48
CYP3A4 P08684 1/20 0.48
BLM P54132 1/20 0.48
KMT2A Q03164 1/20 0.48
MAOA P21397 1/20 0.45
MAOB P27338 1/20 0.45
USP2 O75604 1/20 0.44
ESR1 P03372 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14676268 0.86 KDM4E (0.68) KDM4ECYP26A1CYP26B1FFAR1S1PR1
SCHEMBL979562 0.81 PIM1 (0.59) KDM4EFFAR1S1PR1PIM1PIM2
SCHEMBL25795646 0.79 KDM4E (1.00) KDM4EALDH1A1NPC1MAPK1TP53
SCHEMBL2434363 0.77 KDM4E (0.82) KDM4EALDH1A1NPC1MAPK1NAPRT
SCHEMBL15867533 0.76 CYP19A1 (0.51) KDM4EPIM1PIM2ALDH1A1NPC1
SCHEMBL14677656 0.76 CYP26A1 (0.50) KDM4ECYP26A1CYP26B1FFAR1S1PR1
SCHEMBL22701132 0.76 CYP26B1 (1.00) CYP26A1CYP26B1FFAR1MAOAMAOB
SCHEMBL14684905 0.75 CYP26A1 (0.52) KDM4ECYP26A1CYP26B1PIM1PIM2
SCHEMBL981462 0.74 CYP19A1 (0.64) KDM4ES1PR1PIM1PIM2ALDH1A1
SCHEMBL3941960 0.74 NAPRT (0.67) KDM4EPIM1PIM2ALDH1A1NAPRT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315881-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. 2014-10-23 US disclosed
EP-2736330-A1 COMPOUNDS AND METHODS Tempero Pharmaceuticals, Inc. (US) 2014-06-04 EP disclosed
WO-2013019682-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. (US) 2013-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315881-A1 COMPOUNDS AND METHODS RORC, RORB, RORA KDM4E 1952/4885CYP26A1 165/4885CYP26B1 108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.